- Home
- GUTS vs IFRX Comparison
GUTS vs IFRX Comparison
Compare GUTS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- IFRX
- Stock Information
- Founded
- GUTS 2010
- IFRX 2007
- Country
- GUTS United States
- IFRX Germany
- Employees
- GUTS N/A
- IFRX N/A
- Industry
- GUTS
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- IFRX Health Care
- Exchange
- GUTS NYSE
- IFRX Nasdaq
- Market Cap
- GUTS 58.8M
- IFRX 53.5M
- IPO Year
- GUTS 2024
- IFRX 2017
- Fundamental
- Price
- GUTS $1.92
- IFRX $0.90
- Analyst Decision
- GUTS Buy
- IFRX Strong Buy
- Analyst Count
- GUTS 1
- IFRX 4
- Target Price
- GUTS $10.00
- IFRX $7.75
- AVG Volume (30 Days)
- GUTS 450.6K
- IFRX 356.2K
- Earning Date
- GUTS 08-13-2025
- IFRX 08-07-2025
- Dividend Yield
- GUTS N/A
- IFRX N/A
- EPS Growth
- GUTS N/A
- IFRX N/A
- EPS
- GUTS N/A
- IFRX N/A
- Revenue
- GUTS $60,000.00
- IFRX $140,242.00
- Revenue This Year
- GUTS N/A
- IFRX N/A
- Revenue Next Year
- GUTS N/A
- IFRX $1,276.37
- P/E Ratio
- GUTS N/A
- IFRX N/A
- Revenue Growth
- GUTS N/A
- IFRX 30.90
- 52 Week Low
- GUTS $0.87
- IFRX $0.71
- 52 Week High
- GUTS $4.37
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- GUTS 58.78
- IFRX 52.02
- Support Level
- GUTS $1.84
- IFRX $0.82
- Resistance Level
- GUTS $1.95
- IFRX $0.89
- Average True Range (ATR)
- GUTS 0.11
- IFRX 0.06
- MACD
- GUTS 0.05
- IFRX 0.01
- Stochastic Oscillator
- GUTS 90.00
- IFRX 75.92
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.